HORIZANT Drug Patent Profile

Which patents cover Horizant, and what generic alternatives are available?

Horizant is a drug marketed by Azurity and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-three patent family members in twenty-four countries.

The generic ingredient in HORIZANT is gabapentin enacarbil. There are twenty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the gabapentin enacarbil profile page.

DrugPatentWatch^® Generic Entry Outlook for Horizant

Horizant was eligible for patent challenges on April 6, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 10, 2026. This may change due to patent challenges or generic licensing.

Annual sales in 2022 were $15mm indicating the motivation for generic entry (peak sales were $535mm in 2018).

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (gabapentin enacarbil), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for HORIZANT

International Patents:	73
US Patents:	3
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for HORIZANT

Paragraph IV (Patent) Challenges for HORIZANT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
HORIZANT	Extended-release Tablets	gabapentin enacarbil	300 mg and 600 mg	022399	1	2019-04-29

US Patents and Regulatory Information for HORIZANT

HORIZANT is protected by four US patents.

This potential generic entry date is based on patent 8,026,279.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399-002	Dec 13, 2011		RX	Yes	No	8,114,909
Azurity	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399-001	Apr 6, 2011		RX	Yes	Yes	8,114,909
Azurity	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399-002	Dec 13, 2011		RX	Yes	No	8,026,279		Y	Y
Azurity	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399-001	Apr 6, 2011		RX	Yes	Yes	8,026,279		Y	Y
Azurity	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399-002	Dec 13, 2011		RX	Yes	No	8,795,725		Y

International Patents for HORIZANT

See the table below for patents covering HORIZANT around the world.

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2009131325	ЛЕЧЕНИЕ ИЛИ ПРЕДУПРЕЖДЕНИЕ СИНДРОМА БЕСПОКОЙНЫХ НОГ С ИСПОЛЬЗОВАНИЕМ ПРОЛЕКАРСТВ АНАЛОГОВ ГАМК
Brazil	PI0517227	forma de dosagem oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, método de tratamento de uma doença ou condição
European Patent Office	1404310	FORMES DE DOSAGE DE PROMEDICAMENTS A FAIBLE TOXICITE A BASE D'ANALOGUES DU GABA, ADMINISTREES PAR VOIE ORALE (ORALLY ADMINISTERED DOSAGE FORMS OF GABA ANALOG PRODRUGS HAVING REDUCED TOXICITY)
Hungary	0400183	Gaba-analóg prodrugok csökkentett toxicitású orális dózisformái (ORALLY ADMINISTERED DOSAGE FORMS OF GABA ANALOG PRODRUGS HAVING REDUCED TOXICITY)
Taiwan	200630086	Gaba analog prodrug sustained release oral dosage forms

HORIZANT (Pregabalin Extended-Release): Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

HORIZANT (pregabalin extended-release, ER) is a pharmaceutical product indicated primarily for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN), postherpetic neuralgia (PHN), and for fibromyalgia treatment in the United States. It is an extension of Pfizer’s flagship nerve pain drug, originally marketed as LYRICA (pregabalin). This review analyzes the current market landscape, growth potential, competitive dynamics, regulatory environment, and financial outlook relevant to HORIZANT as a pharmaceutical asset.

---

1. Overview of HORIZANT and Its Market Position

Attribute	Details
Active Ingredient	Pregabalin (Extended-Release formulation)
Indications	Neuropathic pain (DPN, PHN), fibromyalgia
Manufacturer/Distributor	Neurocrine Biosciences (acquired rights from Pfizer in 2017)
FDA Approval Date	June 2014
Formulation	Extended-release capsules

HORIZANT's distinct extended-release formulation aims to improve adherence by reducing dosing frequency (typically twice daily vs. LYRICA’s three-times-daily dose) with a potentially improved side effect profile.

---

2. Market Dynamics

2.1. Addressable Market and Market Size

The key drivers of HORIZANT’s market include:

Segment	Market Size (USD, 2022)	CAGR (2022-2027)	Key Drivers
Diabetic Peripheral Neuropathy (DPN)	~$7.6 billion	5-7%	Rising diabetes prevalence, aging population
Postherpetic Neuralgia (PHN)	~$1.2 billion	6%	Aging population, herpes zoster incidence
Fibromyalgia	~$1.5 billion	4-6%	Increased diagnosis, awareness

Note: The total addressable market is estimated at over $10.3 billion globally, with the U.S. constituting approximately 60% of sales.

2.2. Market Penetration and Competitive Landscape

Competitors	Products	Formulations	Market Share	Notes
Pfizer (Lyricsa)	LYRICA (pregabalin, immediate-release)	Capsule, oral	~70% US	Established first-mover, high brand loyalty
Takeda, Grünenthal, Others	Gabapentin, pregabalin (generic)	Capsule, tablet	~20%	Cost-sensitive segment, generic uptake
Neurocrine Biosciences	HORIZANT (ER pregabalin)	Capsule (ER)	Small but growing	Niche for patients needing twice-daily dosing

Market share trends indicate:

• Generics are penetrating due to cost advantages.
• Brand loyalty favors LYRICA, but extended-release formulations like HORIZANT claim adherence benefits.
• Price pressures are rising, especially in payor-sensitive segments.

2.3. Regulatory and Reimbursement Environment

• FDA regulatory status: Clear approval pathway for extended-release pregabalin.
• Reimbursement landscape: Coverage by major commercial payors; Medicare Part D formulations reimbursable, impacting uptake.
• Patent and exclusivity: The key patents for LYRICA have expired, allowing generics on the market, but HORIZANT’s formulation holds proprietary status until at least 2028.

---

3. Investment and Financial Trajectory

3.1. Revenue Generation Potential

Year	Estimated Revenue (USD millions)	Assumptions
2023	$100 - $150	Early growth phase; increased prescriber awareness
2024	$200 - $250	Market expansion, better payor coverage
2025	$300 - $400	Penetration in new segments; potential formularies including HORIZANT for adherence benefits
2026+	Stabilization or slight decline	Generic competition increases, elasticity in pricing

Note: These forecasts assume favorable new indications, expanded prescriber acceptance, and competitive positioning.

3.2. Cost Structure and Margins

• Manufacturing costs: Marginal, especially with scale.
• Marketing spend: Moderate, focusing on physician education and payor negotiations.
• Profit margins: Estimated at 60-70% gross margin; net margins depend on commercialization costs.

3.3. Key Financial Risks

Risk Factors	Impacts
Generic competition	Price erosion, reduced market share
Regulatory changes	Potentially stricter controls on opioid-like drugs
Reimbursement policies	Favorability or restrictions impact access and sales
Patent litigation	Possible delays or extensions to brand exclusivity

---

4. Comparative Analysis: HORIZANT vs. Key Competitors

Feature	HORIZANT	LYRICA (Pfizer)	Gabapentin (Generics)	Other Neuropathic Pain Drugs
Formulation	Extended-release	Immediate-release	Immediate-release	Varies
Dosing Frequency	Twice daily	Thrice daily	Once or multiple daily doses	Varies
Market Share (est.)	Small but growing	Dominates (>70% in US)	Major share post patent expiry	Niche segments
Pricing	Premium over generics	Premium	Low-cost	Varies
Adherence Potential	Improved due to dosing	Moderate	Variable	Varies

---

5. Long-term Outlook and Strategic Opportunities

Opportunity	Rationale
Expanding indications	New approvals for concomitant neurological conditions
Formulation improvements	Further extended-release or combination therapies
International markets	Growing healthcare infrastructure and diabetes prevalence in Asia & EU
Payor partnerships	Value-based agreements emphasizing adherence benefits
Strategic collaborations	Co-marketing or licensing deals with other pharma firms

---

6. Regulatory and Pricing Policy Landscape

• FDA policies: Favor innovation; latest guidance supports extended-release opioids and similar formulations to improve safety profiles.
• Pricing regulations: Increasing scrutiny on drug prices; direct-to-consumer advertising is subject to regulation.
• Patent policies: Monitoring patent filings, patent term extensions, and potential biosimilar/better-formulation challenges.

---

7. Risks and Challenges

Challenge	Mitigation Strategy
Market penetration barriers	Strategic marketing, payor negotiations, physician education
Pricing pressure due to generic competition	Emphasize therapeutic benefits, adherence, patient outcomes
Regulatory hurdles or potential side effect concerns	Robust clinical data, post-marketing surveillance

---

8. Key Takeaways

• HORIZANT's niche in extended-release pregabalin positions it to capitalize on adherence-driven therapy benefits, especially as payers increasingly favor formulations that improve compliance.
• The primary growth driver remains the expanding prevalence of neuropathic pain conditions, compounded by aging populations and rising diabetes rates.
• Competitive advantages include twice-daily dosing, potential for improved side effect profile, and formulary positioning.
• Market growth could be hampered by generic competition; however, patent protections and formulation advantages provide a window for sustained revenue.
• Strategic focus on international expansion and indication expansion can extend product lifecycle and revenue streams.

---

FAQs

1. How does HORIZANT differ from LYRICA in terms of clinical benefits?
HORIZANT offers an extended-release formulation that reduces dosing frequency (twice daily vs. thrice daily for LYRICA), potentially improving adherence and patient convenience, with some evidence suggesting comparable efficacy and possibly fewer side effects due to steadier plasma levels.

2. What is the competitive threat posed by generics?
Patent expiries for LYRICA have led to aggressive generic penetration, putting pricing pressure on branded formulations like HORIZANT. Market share diminishes unless HORIZANT secures broader formulary inclusion or additional indications.

3. What is the forecasted market size for HORIZANT through 2026?
While precise revenue forecasts vary, the US market for extended-release pregabalin is projected to reach up to $400 million annually, depending on market penetration and competitive dynamics.

4. What factors influence HORIZANT’s reimbursement prospects?
Coverage depends on formulary placement, comparative cost-effectiveness, and demonstrated adherence benefits. Payer policies favoring adherence and reduced dosing may favor HORIZANT’s positioning.

5. Are there ongoing clinical trials that could impact HORIZANT’s market?
Future trials exploring additional indications, combination therapies, or comparative effectiveness could support broader use, provided regulatory approvals are obtained.

---

References

1. IQVIA, “Pharmaceutical Market Reports,” 2022.
2. FDA, “Drug Approval Processes,” 2014.
3. MarketWatch, “Neuropathic Pain Market Forecast,” 2022.
4. Neurocrine Biosciences, “HORIZANT Prescribing Information,” 2014.
5. US Census Bureau, “Population Demographics and Disease Prevalence,” 2022.

---

Disclaimer: This analysis constitutes an overview based on publicly available information as of early 2023 and should not be construed as investment advice.